Rhythm Biosciences Limited (RHY:ASX) Investor Relations Material

Overview

Rhythm Biosciences Limited is an Australian medical diagnostics company that specializes in developing and commercializing cutting-edge technology for the early detection of colorectal cancer. The company's flagship product, ColoSTAT, is a groundbreaking blood test that is set to significantly improve the detection and treatment of this deadly disease. Since its incorporation in 2017, Rhythm Biosciences Limited has established itself as a transformative force in the healthcare industry, with its innovative approach earning it a reputation as a company to watch. With its headquarters located in Parkville, Australia, Rhythm Biosciences Limited is poised to make a major impact on the global healthcare scene in the years to come.

Frequently Asked Questions

What is Rhythm Biosciences Limited's ticker?

Rhythm Biosciences Limited's ticker is RHY

What exchange is Rhythm Biosciences Limited traded on?

The company's shares trade on the ASX stock exchange

Where are Rhythm Biosciences Limited's headquarters?

They are based in Parkville, Australia

How many employees does Rhythm Biosciences Limited have?

There are 11-50 employees working at Rhythm Biosciences Limited

What is Rhythm Biosciences Limited's website?

It is https://www.rhythmbio.com/

What type of sector is Rhythm Biosciences Limited?

Rhythm Biosciences Limited is in the Healthcare sector

What type of industry is Rhythm Biosciences Limited?

Rhythm Biosciences Limited is in the Biotechnology industry

Who are Rhythm Biosciences Limited's peers and competitors?

The following five companies are Rhythm Biosciences Limited's industry peers:

- Intellia Therapeutics

- Incyte

- Cidara Therapeutics Inc

- InflaRx N.V.

- Fulcrum Therapeutics Inc